October 11, 2017 James E. Callaway, Ph.D 4893 Drakewood Terrace San Diego, CA 92130 Dear James:Letter Agreement • March 30th, 2018 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
This Letter Agreement (the "Agreement") is to confirm the terms of your proposed appointment on August 14, 2017 (the "Effective Date") as a non-employee, independent Director of Xenetic Biosciences, Inc. (the "Company").
RIGHT TO SUBLICENSE AGREEMENTRight to Sublicense Agreement • March 30th, 2018 • Xenetic Biosciences, Inc. • Pharmaceutical preparations • Delaware
This Right to Sublicense Agreement (“Agreement”) is made and entered into as of October 27, 2017 by and between Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH (collectively, with their Affiliates, “Baxalta”) and Xenetic Biosciences, Inc. (with its Affiliates, “Xenetic”) (with Baxalta and Xenetic being the “Parties” and each individually, a “Party”).
XENETIC BIOSCIENCES INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 30th, 2018 • Xenetic Biosciences, Inc. • Pharmaceutical preparations • Massachusetts
This Amended and Restated Employment Agreement (“Agreement”) is entered into as of this 26th day of October, 2017 by and between Xenetic Biosciences, Inc., a Nevada corporation with a principal place of business in Lexington, Massachusetts (the “Company”), and Jeffrey Eisenberg, an individual (the “Executive”).
XENETIC BIOSCIENCES (UK) LIMITED and LIPOXEN TECHNOLOGIES LIMITED and XENETIC BIOSCIENCES INC. and MICHAEL SCOTT MAGUIRE SETTLEMENT AGREEMENT Without prejudice and subject to contractSettlement Agreement • March 30th, 2018 • Xenetic Biosciences, Inc. • Pharmaceutical preparations • England and Wales
